LONG-TERM EVOLUTION OF TYPE III ERYTHROCYTES DURING ECULIZUMAB TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA

被引：0
|
作者：
Moncharmont, P. [1 ]
Barraco, F. [2 ]
Bernaud, J. [1 ]
Raffin, A. [1 ]
Michallet, M. [2 ]
Rigal, D. [1 ]
机构：
[1] EFS Rhone Alpes Site Lyon Gerland, Lyon, France
[2] CHLS, Dept Clin Haematol, Pierre Benite, France
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1440
引用
收藏
页码：574 / 575
页数：2
相关论文
共 50 条
  • [41] Long-term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real-world setting
    Versmold, Katharina
    Alashkar, Ferras
    Raiser, Carina
    Ofori-Asenso, Richard
    Xu, Tao
    Liu, Yutong
    Katz, Pablo
    Shang, Aijing
    Roeth, Alexander
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (01) : 84 - 95
  • [42] DAF-deficient erythrocytes during the longterm clinical course of patients with paroxysmal nocturnal haemoglobinuria.
    Mahbub, B
    Kitano, K
    Shimodaira, S
    Ishida, F
    Kiyosawa, K
    Nishimura, J
    Kitani, T
    BLOOD, 1995, 86 (10) : 2535 - 2535
  • [43] Eculizumab treatment for paroxysmal nocturnal haemoglobinuria in a patient with recurrent simultaneous multivessel coronary stent thrombosis
    De Maria, Giovanni Luigi
    Sarwar, Rizwan
    Banning, Adrian P.
    OXFORD MEDICAL CASE REPORTS, 2015, (01): : 167 - 169
  • [44] Complement inhibition with Eculizumab affects fibrinogen levels and clot Structure in patients with Paroxysmal Nocturnal Haemoglobinuria
    Macrae, F.
    Bowman, P.
    Linton, E.
    Peacock-Young, B.
    Clarke, D.
    Newton, D.
    McKinley, C.
    Riley, K.
    Copeland, N.
    Arnold, L.
    Ariens, R.
    Hill, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 130 - 130
  • [45] Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab
    van Bijnen, Sandra T. A.
    van Rijn, Roos S.
    Koljenovic, Senada
    te Boekhorst, Peter
    de Witte, Theo
    Muus, Petra
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (06) : 762 - 763
  • [46] EXTRAVASCULAR HEMOLYSIS DURING TREATMENT WITH ECULIZUMAB FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Graciaa, Sara
    Chonat, Satheesh
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [47] Characterization of paroxysmal nocturnal hemoglobinuria (PNH) type III erythrocytes
    Shichishimal, T
    Saitohl, Y
    Kirito, K
    Nakamura, M
    Terasawal, T
    Maruyamal, Y
    BLOOD, 1996, 88 (10) : 1208 - 1208
  • [48] Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival
    Kelly, Richard J.
    Hill, Anita
    Mitchell, Lindsay D.
    Richards, Stephen John
    Arnold, Louise M.
    Valters, Gemma L.
    Cullen, Matthew
    Cohen, Dena R.
    Gregory, Walter M.
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 280 - 281
  • [49] DECAY-ACCELERATING-FACTOR-DEFICIENT ERYTHROCYTES DURING THE LONG-TERM CLINICAL COURSE OF PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA
    MAHBUB, B
    NISHIMURA, J
    KITANI, T
    KITANO, K
    ACTA HAEMATOLOGICA, 1995, 93 (2-4) : 91 - 97
  • [50] INDUCTION CHEMOTHERAPY AND ECULIZUMAB TREATMENT OF HIGH-RISK MYELODYSPLASIA WITH A LARGE PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA CLONE
    Cross, J.
    Johansson, U.
    Besley, C.
    Protheroe, R.
    Kulasekararaj, A.
    Mehta, P.
    LEUKEMIA RESEARCH, 2021, 108 : S29 - S29
12345